Topic: peripheral artery disease
AstraZeneca has made a hefty investment in Brilinta with billions in R&D costs. But will that sunk cost ever turn a profit for the British drugmaker?
The FDA approved Xarelto for chronic coronary or peripheral artery disease, an indication analysts said is worth $1.5 billion.
With a new study in patients with peripheral artery disease, Johnson & Johnson has once again bolstered its case for another Xarelto approval.
Johnson & Johnson's Xarelto has more results to back up its artery disease case—and help it extend its indication lead over the competition.
Over the weekend, J&J's under-presser Xarelto got a big boost that could expand its potential treatment population by more than half.
Survivors are at the heart of AstraZeneca's new DTC campaign for clot-fighter Brilinta.
Johnson & Johnson and Bayer have some positive trial results in hand that could help bolster under-fire Xarelto's market position.